阿托伐他汀对缺血性脑血管病C-反应蛋白及血脂的影响

目的探讨阿托伐他汀（立普妥）对脑梗死及短暂性脑缺血发作患者C．反应蛋白（C-reactireprotein，CRP）及血脂的影响。方法将120例伴有颈动脉粥样硬化斑块的脑梗死及短暂性脑缺血发作患者随机分为治疗组与对照组；治疗组口服阿托伐他汀及抗血小板聚集等常规治疗，对照组仅予抗血小板聚集等常规治疗，于治疗前、治疗后3个月、治疗后6个月对血脂和C-反应蛋白进行检测比较治疗前后各指标的变化情况。结果使用阿托伐他汀治疗后患者血清C-反应蛋白、胆固醇、甘油三脂、低密度脂蛋白显著降低；高密度脂蛋白在治疗前后无统计学差异。结论阿托伐他汀可以有效降低LDL-C和TC水平，同时能够明显降低CRP的浓度。

Effects of the Atorvastatin on C-reactive protein and blood lipid on patients suffer with ischemix stroke

Objective To explore the effect of Atorvastatin on C-reactive protein and blood lipid in patients suffering cerebral infarction（CI） and transient ischemic attack（TIA）. Methods 120 patients with CI and TIA were randomly divided into therapy group and control group, and the patients in control group were only given anti-platelet aggregation as routine treatment, however, the patients in therapy group were administered antiplatelet aggregation and atorvastatin 20 mg every night. The duration of follow-up was 3 to 6 months. Before and after treatment, the levels of CRP and blood lipid were measured. Results The levels of LDL-C, cholesterol, triglycerides and CRP decreased significantly after Atorvastatin therapy, and the levels of HDL-C were not statistics difference between before and after Atorvastatin therapy. Conclusion Atorvastatin can decrease the level of LDL-C,TC and CRP in patients suffering CI.